38 related articles for article (PubMed ID: 11349832)
1. Whole-genome Sequencing of Follicular Thyroid Carcinomas Reveal Recurrent Mutations in MicroRNA Processing Subunit DGCR8.
Paulsson JO; Rafati N; DiLorenzo S; Chen Y; Haglund F; Zedenius J; Juhlin CC
J Clin Endocrinol Metab; 2021 Oct; 106(11):3265-3282. PubMed ID: 34171097
[TBL] [Abstract][Full Text] [Related]
2. Akt isoform-specific effects on thyroid cancer development and progression in a murine thyroid cancer model.
Saji M; Kim CS; Wang C; Zhang X; Khanal T; Coombes K; La Perle K; Cheng SY; Tsichlis PN; Ringel MD
Sci Rep; 2020 Oct; 10(1):18316. PubMed ID: 33110146
[TBL] [Abstract][Full Text] [Related]
3. Diosgenin and Its Fenugreek Based Biological Matrix Affect Insulin Resistance and Anabolic Hormones in a Rat Based Insulin Resistance Model.
Kiss R; Pesti-Asbóth G; Szarvas MM; Stündl L; Cziáky Z; Hegedűs C; Kovács D; Badale A; Máthé E; Szilvássy Z; Remenyik J
Biomed Res Int; 2019; 2019():7213913. PubMed ID: 31080828
[TBL] [Abstract][Full Text] [Related]
4. An in vivo model for thyroid regeneration and folliculogenesis.
Iwadate M; Takizawa Y; Shirai YT; Kimura S
Lab Invest; 2018 Sep; 98(9):1126-1132. PubMed ID: 29946134
[TBL] [Abstract][Full Text] [Related]
5. Pax-8-PPAR-γ fusion protein in thyroid carcinoma.
Raman P; Koenig RJ
Nat Rev Endocrinol; 2014 Oct; 10(10):616-23. PubMed ID: 25069464
[TBL] [Abstract][Full Text] [Related]
6. Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.
Malaguarnera R; Chen KY; Kim TY; Dominguez JM; Voza F; Ouyang B; Vundavalli SK; Knauf JA; Fagin JA
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1976-87. PubMed ID: 25029414
[TBL] [Abstract][Full Text] [Related]
7. Apigenin in combination with Akt inhibition significantly enhances thyrotropin-stimulated radioiodide accumulation in thyroid cells.
Lakshmanan A; Doseff AI; Ringel MD; Saji M; Rousset B; Zhang X; Jhiang SM
Thyroid; 2014 May; 24(5):878-87. PubMed ID: 24400871
[TBL] [Abstract][Full Text] [Related]
8. Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.
Martin CK; Dirksen WP; Carlton MM; Lanigan LG; Pillai SP; Werbeck JL; Simmons JK; Hildreth BE; London CA; Toribio RE; Rosol TJ
Vet Comp Oncol; 2015 Sep; 13(3):203-17. PubMed ID: 23651067
[TBL] [Abstract][Full Text] [Related]
9. Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer.
Saji M; Narahara K; McCarty SK; Vasko VV; La Perle KM; Porter K; Jarjoura D; Lu C; Cheng SY; Ringel MD
Oncogene; 2011 Oct; 30(42):4307-15. PubMed ID: 21532616
[TBL] [Abstract][Full Text] [Related]
10. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.
Sozopoulos E; Litsiou H; Voutsinas G; Mitsiades N; Anagnostakis N; Tseva T; Patsouris E; Tseleni-Balafouta S
Endocr Pathol; 2010 Jun; 21(2):90-100. PubMed ID: 20186503
[TBL] [Abstract][Full Text] [Related]
11. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.
Saji M; Ringel MD
Mol Cell Endocrinol; 2010 May; 321(1):20-8. PubMed ID: 19897009
[TBL] [Abstract][Full Text] [Related]
12. The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer.
Eberhardt NL; Grebe SK; McIver B; Reddi HV
Mol Cell Endocrinol; 2010 May; 321(1):50-6. PubMed ID: 19883731
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of sorafenib in metastatic thyroid cancer.
Kloos RT; Ringel MD; Knopp MV; Hall NC; King M; Stevens R; Liang J; Wakely PE; Vasko VV; Saji M; Rittenberry J; Wei L; Arbogast D; Collamore M; Wright JJ; Grever M; Shah MH
J Clin Oncol; 2009 Apr; 27(10):1675-84. PubMed ID: 19255327
[TBL] [Abstract][Full Text] [Related]
14. A novel Epac-Rap-PP2A signaling module controls cAMP-dependent Akt regulation.
Hong K; Lou L; Gupta S; Ribeiro-Neto F; Altschuler DL
J Biol Chem; 2008 Aug; 283(34):23129-38. PubMed ID: 18550542
[TBL] [Abstract][Full Text] [Related]
15. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells.
Mandal M; Kim S; Younes MN; Jasser SA; El-Naggar AK; Mills GB; Myers JN
Br J Cancer; 2005 May; 92(10):1899-905. PubMed ID: 15870708
[TBL] [Abstract][Full Text] [Related]
16. Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization.
Motti ML; Califano D; Troncone G; De Marco C; Migliaccio I; Palmieri E; Pezzullo L; Palombini L; Fusco A; Viglietto G
Am J Pathol; 2005 Mar; 166(3):737-49. PubMed ID: 15743786
[TBL] [Abstract][Full Text] [Related]
17. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer.
Vasko V; Saji M; Hardy E; Kruhlak M; Larin A; Savchenko V; Miyakawa M; Isozaki O; Murakami H; Tsushima T; Burman KD; De Micco C; Ringel MD
J Med Genet; 2004 Mar; 41(3):161-70. PubMed ID: 14985374
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.
Poulaki V; Mitsiades CS; Kotoula V; Tseleni-Balafouta S; Ashkenazi A; Koutras DA; Mitsiades N
Am J Pathol; 2002 Aug; 161(2):643-54. PubMed ID: 12163389
[TBL] [Abstract][Full Text] [Related]
19. Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling.
Saito J; Kohn AD; Roth RA; Noguchi Y; Tatsumo I; Hirai A; Suzuki K; Kohn LD; Saji M; Ringel MD
Thyroid; 2001 Apr; 11(4):339-51. PubMed ID: 11349832
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
